Literature DB >> 14730654

Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center.

Tim W R Lee1, Keith G Brownlee, Miles Denton, James M Littlewood, Steven P Conway.   

Abstract

Various management strategies were introduced at the Leeds Regional Cystic Fibrosis (CF) Unit in an attempt to reduce the prevalence of chronic Pseudomonas aeruginosa respiratory infection, previously thought to be inevitable in most children with CF. These included neonatal screening (1975), regular microbiological monitoring (1975), early antibiotic treatment of first isolations of P. aeruginosa (1985), intensive intravenous antibiotic treatment where nebulized antibiotics failed to eradicate P. aeruginosa (1988), and separate clinics for patients chronically infected with P. aeruginosa and uninfected patients (1991). The aim of this study was to assess the impact of these interventions. All 232 patients receiving full-time care at the Leeds Paediatric CF Centre during the period January 1990-December 2000 were categorized into four groups: never grown P. aeruginosa; free of P. aeruginosa for at least 1 year; intermittent grower of P. aeruginosa with </=50% of months with samples positive for P. aeruginosa over the previous 12 months; and chronic P. aeruginosa infection with >50% of months with samples positive for P. aeruginosa over the previous 12 months. The yearly prevalence of patients having chronic P. aeruginosa infection fell significantly during the study, from 24.5% in 1990 to 18.1% in 2000 (P < 0.05), despite an increase in mean age of patients from 7.73 to 9.42 years. The number of patients aged less than 11 years who had chronic P. aeruginosa infection fell from 23.8% in January 1990 to only 4.3% by December 2000. The annual incidence and mean age of first acquisition of P. aeruginosa did not alter significantly. In conclusion, antipseudomonal management strategies were associated with both reduced prevalence, and an increase in the mean age of onset of chronic P. aeruginosa infection. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14730654     DOI: 10.1002/ppul.10401

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  18 in total

Review 1.  Fungal Pathogens in CF Airways: Leave or Treat?

Authors:  A Singh; A Ralhan; C Schwarz; D Hartl; A Hector
Journal:  Mycopathologia       Date:  2017-08-02       Impact factor: 2.574

2.  Impact of Sustained Eradication of New Pseudomonas aeruginosa Infection on Long-term Outcomes in Cystic Fibrosis.

Authors:  Nicole Mayer-Hamblett; Margaret Kloster; Margaret Rosenfeld; Ronald L Gibson; George Z Retsch-Bogart; Julia Emerson; Valeria Thompson; Bonnie W Ramsey
Journal:  Clin Infect Dis       Date:  2015-05-13       Impact factor: 9.079

3.  Neurotrophic and neuroimmune responses to early-life Pseudomonas aeruginosa infection in rat lungs.

Authors:  Silvia Cardenas; Mario Scuri; Lennie Samsell; Barbara Ducatman; Pablo Bejarano; Alexander Auais; Melissa Doud; Kalai Mathee; Giovanni Piedimonte
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-06-11       Impact factor: 5.464

4.  Virulence factor expression patterns in Pseudomonas aeruginosa strains from infants with cystic fibrosis.

Authors:  J Manos; H Hu; B R Rose; C E Wainwright; I B Zablotska; J Cheney; L Turnbull; C B Whitchurch; K Grimwood; C Harmer; S N Anuj; C Harbour
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-07-07       Impact factor: 3.267

5.  Changing Rates of Chronic Pseudomonas aeruginosa Infections in Cystic Fibrosis: A Population-Based Cohort Study.

Authors:  Matthew R Crull; Ranjani Somayaji; Kathleen J Ramos; Ellen Caldwell; Nicole Mayer-Hamblett; Moira L Aitken; David P Nichols; Ali Rowhani-Rahbar; Christopher H Goss
Journal:  Clin Infect Dis       Date:  2018-09-14       Impact factor: 9.079

6.  Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.

Authors:  Sonya L Heltshe; Nicole Mayer-Hamblett; Jane L Burns; Umer Khan; Arthur Baines; Bonnie W Ramsey; Steven M Rowe
Journal:  Clin Infect Dis       Date:  2014-11-25       Impact factor: 9.079

7.  Pseudomonas infection in antibody deficient patients.

Authors:  Sai S Duraisingham; Steven Hanson; Matthew Buckland; Sofia Grigoriadou; Hilary J Longhurst
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2014-12-16

8.  Recovery of birth weight z score within 2 years of diagnosis is positively associated with pulmonary status at 6 years of age in children with cystic fibrosis.

Authors:  Huichuan J Lai; Suzanne M Shoff; Philip M Farrell
Journal:  Pediatrics       Date:  2009-02       Impact factor: 7.124

Review 9.  Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis.

Authors:  Matthew N Hurley; Douglas L Forrester; Alan R Smyth
Journal:  Cochrane Database Syst Rev       Date:  2013-06-05

Review 10.  [Chronic Pseudomonas aeruginosa airway colonization in cystic fibrosis patients : Prevention concepts].

Authors:  A-M Dittrich
Journal:  Internist (Berl)       Date:  2017-11       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.